New research suggests that individuals who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who stop traditional diet and exercise plans.
Findings released in a leading health publication demonstrates that while overweight people often shed about a fifth of their body weight while on the medication, the weight is regained at an estimated rate of 0.8 kg per month once they quit.
"People using these treatments should be informed of the risk of fast rebound weight gain when the therapy ends," stated researcher Dr. Susan Jebb.
This pace of recovery implies a return to original mass within about 18 months.
Analyzing Treatments
The analysis, which reviewed 37 of studies involving over 9,000 of patients, compared the results of GLP-1 agonists with older methods.
Scientists emphasize that individuals who shed pounds through dieting generally experience a slower weight regain—perhaps 0.1 kg a month—post-intervention.
Explaining the Quick Rebound
Doctors believe the mechanism of the injections is key to understanding the heightened weight return.
The injections copy a body's own chemical called GLP-1, which moderates appetite.
"Sustained high doses of GLP-1 levels several times higher than the body's typical production may cause the body to generate a reduced amount of its endogenous GLP-1, and may also lessen sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this medication results in hunger is unsuppressed, making excessive eating a significant risk."
A Chronic Condition?
Health authorities advise the injections for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Many experts contend that, given the likelihood of weight regain, the treatment should be considered long-term.
This perspective is reinforced by pharmaceutical companies, who say that the results "highlight the persistent nature of excess weight," akin to managing diseases like high blood pressure.
Patient Testimonies
Users who have discontinued the medication report a sudden return of cravings.
"I experienced something flipping and you're instantly ravenous," recalled an individual.
This challenge is worsened if users have not established sustainable dietary or behavioural changes during treatment.
Significant Interest
Survey data indicate that millions of adults in the UK have tried these injections in the last 12 months, with desire remaining high.
- Adoption is higher among females compared to men.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
Finally, experts stress that while these medications are effective tools for weight loss, they are not a magic cure and maintained weight loss relies on integrated lifestyle management.
